Viatris (NASDAQ: VTRS) shares skidded 24% yesterday to $11.01 after announcing it would sell its biosimilars portfolio to Biocon Biologics for as much as $3.335 billion. The former company unveiled the news when announcing its fourth-quarter earnings. Viatris will pay $2 billion upfront, $1 billion in convertible preferred equity, and $335 million in additional payments…